A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Conditions
- Crohn's Disease
- Interventions
- Drug: IV TulisokibartDrug: SC TulisokibartOther: IV PlaceboOther: SC Placebo
- Registration Number
- NCT06430801
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
- Detailed Description
The protocol consists of 2 studies. Study 1 includes induction and maintenance treatment, and Study 2 includes only induction treatment. Each study has its own hypotheses and outcome measures that will be assessed independently.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1200
- Has had a diagnosis of CD at least 3 months before study.
- Has moderately to severely active CD.
- Demonstrated inadequate response, loss of response, or intolerance to one or more of the following categories of drugs: oral locally acting steroids, systemic steroids, immunomodulators, biologic and/or small molecule advanced therapies.
- Adolescent participants ≥16 and <18 years of age can participate if approved by the country or regulatory/health authority.
- Has diagnosis of ulcerative colitis (UC) or indeterminate colitis.
- Has CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and/or ileal involvement.
- Currently has any of the following complications of CD: suspected or diagnosed with intra-abdominal or perianal abscess, known symptomatic stricture or colonic stenosis not passable in endoscopy, fulminant colitis, toxic megacolon, or any other manifestation that might require surgery while enrolled in the study.
- Has current stoma or need for colostomy or ileostomy.
- Is missing >2 segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum.
- Has been diagnosed with short gut or short bowel syndrome, or any other uncontrolled chronic diarrhea besides Crohn's disease.
- Has surgical bowel resection within 3 months of study.
- Has prior or current gastrointestinal dysplasia.
- Has chronic infection requiring ongoing antimicrobial treatment.
- Has a history of cancer (except fully treated non-melanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for <5 years.
- Is infected with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- Has active tuberculosis.
- Has confirmed or suspected coronavirus disease of 2019 (COVID-19) infection.
- Prior exposure to tulisokibart (MK-7240, PRA023) or another anti-TL1A antibody.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Study 1: High Dose Induction, High Dose Maintenance IV Tulisokibart Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen. Study 1: High Dose Induction, High Dose Maintenance SC Tulisokibart Participants receive high dose intravenous (IV) tulisokibart, followed by a high dose subcutaneous (SC) tulisokibart regimen. Study 1: High Dose Induction, Low Dose Maintenance IV Tulisokibart Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen. Study 1: High Dose Induction, Low Dose Maintenance SC Tulisokibart Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen. Study 1: High Dose Induction, Low Dose Maintenance SC Placebo Participants receive high dose IV tulisokibart, followed by a low dose SC tulisokibart regimen. Study 1: Low Dose Induction, Low Dose Maintenance IV Tulisokibart Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen. Study 1: Low Dose Induction, Low Dose Maintenance SC Tulisokibart Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen. Study 1: Low Dose Induction, Low Dose Maintenance SC Placebo Participants receive low dose IV tulisokibart, followed by a low dose SC tulisokibart regimen. Study 1: Placebo IV Tulisokibart Participants receive IV placebo, followed by an SC placebo regimen. Study 1: Placebo IV Placebo Participants receive IV placebo, followed by an SC placebo regimen. Study 1: Placebo SC Placebo Participants receive IV placebo, followed by an SC placebo regimen. Study 1: High Dose Extension SC Tulisokibart Participants receive a high dose SC tulisokibart regimen. Participants may continue in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites. Study 1: Low Dose Extension SC Tulisokibart Participants receive a low dose SC tulisokibart and placebo regimen. Participants may continue in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites. Study 1: Low Dose Extension SC Placebo Participants receive a low dose SC tulisokibart and placebo regimen. Participants may continue in this arm after completing participation in their original arm, if they meet protocol-specific prerequisites. Study 2: High Dose Induction IV Tulisokibart Participants receive high dose IV tulisokibart. Study 2: Low Dose Induction IV Tulisokibart Participants receive low dose IV tulisokibart. Study 2: Low Dose Induction SC Placebo Participants receive low dose IV tulisokibart. Study 2: Placebo IV Tulisokibart Participants receive IV placebo. Study 2: Placebo IV Placebo Participants receive IV placebo. Study 2: Placebo SC Placebo Participants receive IV placebo. Study 2: High Dose Extension SC Tulisokibart Participants receive a high dose SC tulisokibart regimen. Participants may continue in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites. Study 2: Low Dose Extension SC Tulisokibart Participants receive a low dose SC tulisokibart regimen. Participants may continue in this arm only after completing participation in their original arm, if they meet protocol-specific prerequisites.
- Primary Outcome Measures
Name Time Method Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Crohn's Disease Activity Index (CDAI) Score at Week 52 Week 52 The percentage of participants achieving clinical remission, as defined by CDAI score \<150 for study 1 will be presented.
Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52 Week 52 The percentage of participants achieving clinical remission per stool frequency/abdominal pain score (SF/APS), as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline for study 1 will be presented.
Study 1: Percentage of Participants Achieving Endoscopic Response at Week 52 Week 52 The percentage of participants achieving endoscopic response, as defined by a ≥50% decrease in Simplified endoscopic score for Crohn's disease (SES-CD) from baseline for study 1 will be presented.
Study 1: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12 Week 12 The percentage of participants achieving clinical remission, as defined by CDAI score \<150 for study 1 will be presented.
Study 1: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12 Week 12 The percentage of participants achieving clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline for study 1 will be presented.
Study 1: Percentage of Participants Achieving Endoscopic Response at Week 12 Week 12 The percentage of participants achieving endoscopic response, as defined by a ≥50% decrease in SES-CD from baseline for study 1 will be presented.
Study 2 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12 Week 12 The percentage of participants achieving clinical remission, as defined by CDAI score \<150 for study 2 will be presented.
Study 2 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12 Week 12 The percentage of participants achieving clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline for study 2 will be presented.
Study 2: Percentage of Participants Achieving Endoscopic Response at Week 12 Week 12 The percentage of participants achieving endoscopic response, as defined by a ≥50% decrease in SES-CD from baseline for study 2 will be presented.
- Secondary Outcome Measures
Name Time Method Study 1: Percentage of Participants Who Experienced an Adverse Event (AE) Up to approximately 52 weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience an AE for study 1 will be presented.
Study 1: Percentage of Participants who Discontinue Study Intervention due to an AE Up to approximately 52 weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study intervention due to an AE for study 1 will be presented.
Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12 Week 12 The percentage of participants achieving clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline for study 1 will be presented.
Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12 Week 12 The percentage of participants achieving clinical remission, as defined by CDAI score \<150 for study 1 will be presented.
Study 1: Percentage of Participants with Decrease of ≥100 Points in CDAI Score from Baseline to Week 12 Week 12 The percentage of participants achieving a reduction in CDAI ≥100 points from baseline for study 1 will be presented.
Study 1: Mean Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12 Baseline and Week 12 The FACIT-Fatigue is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, scored on a 0 to 52-point scale, with lower scores indicating greater fatigue. The mean change from baseline in FACIT-Fatigue score for study 1 will be presented.
Study 1: Percentage of Participants Achieving Endoscopic Remission at Week 12 Week 12 The percentage of participants achieving endoscopic remission, as defined by SES-CD ≤4 and at least 2-point reduction from baseline and no subscore \>1 in any individual variable for study 1 will be presented. SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing), each on a scale from 0 to 3, in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, left colon/sigmoid, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Study 1 and 2: Percentage of Participants in Diagnostic Assay Positive (Dx+) Subpopulation Achieving Clinical Remission per CDAI at Week 12 Week 12 Dx+ participants are those who meet protocol-specific diagnostic assay criteria during screening. The percentage of Dx+ participants achieving clinical remission, as defined by CDAI score \<150 for study 1 and study 2 will be presented.
Study 1 and 2: Percentage of Participants in Diagnostic Assay Positive (Dx+) Subpopulation Achieving Endoscopic Response at Week 12 Week 12 Dx+ participants are those who meet protocol-specific diagnostic assay criteria during screening. The percentage of Dx+ participants achieving endoscopic response, as defined by a ≥50% decrease in simplified endoscopic score for Crohn's disease (CD) from baseline for study 1 and study 2 will be presented.
Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52 Week 52 The percentage of participants achieving clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline for study 1 will be presented.
Study 1: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 52 Week 52 The percentage of participants achieving clinical remission, as defined by CDAI score \<150 for study 1 will be presented.
Study 1: Percentage of Participants with Decrease of ≥100 Points in CDAI Score from Baseline to Week 52 Week 52 The percentage of participants achieving a reduction in CDAI ≥ 100 points from baseline for study 1 will be presented.
Study 1: Percentage of Participants Achieving Endoscopic Remission at Week 52 Week 52 The percentage of participants achieving endoscopic remission, as defined by SES-CD ≤4 and at least 2-point reduction from baseline and no subscore \>1 in any individual variable for study 1 will be presented. SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing), each on a scale from 0 to 3, in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, left colon/sigmoid, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Study 1: Percentage of Participants Achieving Sustained Clinical Remission per CDAI at Both Week 12 and Week 52 Week 12 and Week 52 The percentage of participants achieving sustained clinical remission, as defined by CDAI score \<150 for study 1 will be presented.
Study 1: Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per CDAI Score at Week 52 Week 52 The percentage of participants who are in clinical remission as defined by CDAI score \<150 and without corticosteroid use for CD at least 90 days prior to that assessment for study 1 will be presented.
Study 1: Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52 Week 52 The percentage of participants who are in clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline and without corticosteroid use for CD at least 90 days prior to that assessment for study 1 will be presented.
Study 1: Percentage of Participants Achieving Clinical Remission per Stool Frequency, Abdominal Pain Score, and Endoscopic Remission at Week 52 Week 52 The percentage of participants achieving clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline and achieving endoscopic remission, as defined by SES-CD ≤4 and at least 2-point reduction from baseline and no subscore \>1 in any individual variable for study 1 will be presented.
Study 1: Percentage of Participants Achieving Clinical Remission per CDAI and Endoscopic Remission at Week 52 Week 52 The percentage of participants achieving clinical remission as defined by CDAI score \<150 and achieving endoscopic remission, as defined by SES-CD ≤4 and at least 2-point reduction from baseline and no subscore \>1 in any individual variable for study 1 will be presented.
Study 1: Mean Change from Baseline in FACIT-Fatigue Score at Week 52 Baseline and Week 52 The FACIT-Fatigue is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, scored on a 0 to 52-point scale, with lower scores indicating greater. The mean change from baseline in FACIT-Fatigue score for study 1 will be presented.
Study 1: Mean Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 52 Baseline and Week 52 The IBDQ measures health related quality of life in participants with inflammatory bowel disease. It consists of 32 questions each with a graded response of 1 (worst) to 7 (best). The score ranges between 32 to 224 with higher scores indicating a better quality of life. The mean change from baseline in IBDQ score for study 1 will be presented.
Study 1: Percentage of Participants with Ulcer-Free Endoscopy at Week 52 Week 52 The percentage of participants achieving ulcer-free endoscopy (mucosal healing), as defined by SES-CD ulcerated surface subscore of 0 in participants with SES-CD ulcerated surface subscore ≥1 at baseline for study 1 will be presented.
Study 2: Percentage of Participants Who Experienced an AE Up to approximately 12 weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience an AE for study 2 will be presented.
Study 2: Percentage of Participants who Discontinue Study Intervention due to an AE Up to approximately 12 weeks An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study intervention due to an AE for study 2 will be presented.
Study 2 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12 Week 12 The percentage of participants achieving clinical remission per SF/APS, as defined by average daily SF ≤2.8 and average daily APS ≤1.0 and both not greater than baseline for study 2 will be presented.
Study 2 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12 Week 12 The percentage of participants achieving clinical remission, as defined by CDAI score \<150 for study 2 will be presented.
Study 2: Percentage of Participants with Decrease of ≥100 Points in CDAI Score from Baseline to Week 12 Week 12 The percentage of participants achieving a reduction in CDAI ≥ 100 points from baseline for study 2 will be presented.
Study 2: Mean Change from Baseline in FACIT-Fatigue Score at Week 12 Baseline and Week 12 The FACIT-Fatigue is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function, scored on a 0 to 52-point scale, with lower scores indicating greater. The mean change from baseline in FACIT-Fatigue score for study 2 will be presented.
Study 2: Percentage of Participants Achieving Endoscopic Remission at Week 12 Week 12 The percentage of participants achieving endoscopic remission, as defined by SES-CD ≤4 and at least 2-point reduction from baseline and no subscore \>1 in any individual variable for study 2 will be presented. SES-CD evaluates 4 endoscopic variables (ulcer size, ulcerated surface, affected surface, and narrowing), each on a scale from 0 to 3, in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, left colon/sigmoid, and rectum). The total score is the sum of the 4 endoscopic variable scores and ranges from 0 to 56, where higher scores indicate more severe disease.
Study 2: Mean Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 12 Baseline and Week 12 The IBDQ measures health related quality of life in participants with inflammatory bowel disease. It consists of 32 questions each with a graded response of 1 (worst) to 7 (best). The score ranges between 32 to 224 with higher scores indicating a better quality of life. The mean change from baseline in IBDQ score for study 2 will be presented.
Study 2: Percentage of Participants with Decrease of ≥100 Points in CDAI Score from Baseline to Week 6 Week 6 The percentage of participants achieving a reduction in CDAI ≥ 100 points from baseline for study 2 will be presented.
Study 2: The percentage of Participants with Ulcer-Free Endoscopy at Week 12 Week 12 The percentage of participants achieving ulcer-free endoscopy (mucosal healing), as defined by SES-CD ulcerated surface subscore of 0 in participants with SES-CD ulcerated surface subscore ≥1 at baseline for study 1 will be presented.
Trial Locations
- Locations (371)
Digestive Health Specialists ( Site 5064)
🇺🇸Dothan, Alabama, United States
GI Alliance - Sun City ( Site 5118)
🇺🇸Sun City, Arizona, United States
University of Arizona Clinical and Translational Sciences Research Center ( Site 5111)
🇺🇸Tucson, Arizona, United States
Clinnova Research ( Site 5110)
🇺🇸Anaheim, California, United States
Om Research LLC ( Site 5045)
🇺🇸Camarillo, California, United States
Southern California Research Center ( Site 5044)
🇺🇸Coronado, California, United States
Om Research LLC ( Site 5038)
🇺🇸Lancaster, California, United States
Amicis Research Center - Valencia ( Site 5055)
🇺🇸Valencia, California, United States
University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 5026)
🇺🇸Aurora, Colorado, United States
Peak Gastroenterology Associates ( Site 5023)
🇺🇸Colorado Springs, Colorado, United States
Medical Research Center of Connecticut ( Site 5005)
🇺🇸Hamden, Connecticut, United States
Emerson Clinical Research Institute ( Site 5051)
🇺🇸Washington, District of Columbia, United States
Gastroenterology Consultants of Clearwater ( Site 5052)
🇺🇸Clearwater, Florida, United States
Nature Coast Clinical Research - Inverness ( Site 5042)
🇺🇸Inverness, Florida, United States
Atlantic Medical Research ( Site 5073)
🇺🇸Margate, Florida, United States
Endoscopic Research Inc ( Site 5061)
🇺🇸Orlando, Florida, United States
Orlando Health-Digestive Health Institute ( Site 5010)
🇺🇸Orlando, Florida, United States
Atlanta Center for Gastroenterology ( Site 5035)
🇺🇸Decatur, Georgia, United States
Gastroenterology Associates of Central Georgia ( Site 5048)
🇺🇸Macon, Georgia, United States
Eagle Clinical Research ( Site 5089)
🇺🇸Chicago, Illinois, United States
University of Chicago Medical Center ( Site 5066)
🇺🇸Chicago, Illinois, United States
Endeavor Health ( Site 5018)
🇺🇸Evanston, Illinois, United States
GI ALLIANCE - GURNEE ( Site 5003)
🇺🇸Gurnee, Illinois, United States
Indiana University Health University Hospital ( Site 5022)
🇺🇸Indianapolis, Indiana, United States
Iowa Digestive Disease Center ( Site 5007)
🇺🇸Clive, Iowa, United States
Cotton O'Neil Digestive Health Center ( Site 5033)
🇺🇸Topeka, Kansas, United States
Southern Clinical Research ( Site 5095)
🇺🇸Zachary, Louisiana, United States
GI Alliance: Mansfield ( Site 5015)
🇺🇸Mansfield, Texas, United States
University of Michigan ( Site 5060)
🇺🇸Ann Arbor, Michigan, United States
Clinical Research Institute of Michigan, LLC ( Site 5002)
🇺🇸Clinton Township, Michigan, United States
BVL Research - Kansas ( Site 5099)
🇺🇸Liberty, Missouri, United States
Washington University School of Medicine ( Site 5058)
🇺🇸Saint Louis, Missouri, United States
HMHN Justice Marie Garibaldi Medical Plaza ( Site 5072)
🇺🇸Hackensack, New Jersey, United States
Northwell Health Division of Gastroenterology at Great Neck ( Site 5017)
🇺🇸Great Neck, New York, United States
Southern Star Research Institute ( Site 5000)
🇺🇸San Antonio, Texas, United States
Circuit Clinical /Crystal Run Healthcare LLP ( Site 5050)
🇺🇸Middletown, New York, United States
NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078)
🇺🇸New York, New York, United States
Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079)
🇺🇸New York, New York, United States
New York Gastroenterology Associates ( Site 5013)
🇺🇸New York, New York, United States
University of North Carolina Medical Center ( Site 5034)
🇺🇸Chapel Hill, North Carolina, United States
Atrium Health Gastroenterology MMP ( Site 5105)
🇺🇸Charlotte, North Carolina, United States
Javara - Tryon Medical Partners ( Site 5046)
🇺🇸Charlotte, North Carolina, United States
Great Lakes Gastroenterology Research, LLC ( Site 5016)
🇺🇸Mentor, Ohio, United States
Digestive Disease Specialists Inc. ( Site 5117)
🇺🇸Oklahoma City, Oklahoma, United States
Frontier Clinical Research, LLC ( Site 5098)
🇺🇸Uniontown, Pennsylvania, United States
University Gastroenterology - Providence - West River Street ( Site 5057)
🇺🇸Providence, Rhode Island, United States
Vanderbilt Inflammatory Bowel Disease Clinic ( Site 5049)
🇺🇸Nashville, Tennessee, United States
Quality Medical Research ( Site 5114)
🇺🇸Nashville, Tennessee, United States
Baylor University Medical Center ( Site 5031)
🇺🇸Dallas, Texas, United States
GI Alliance - Dallas - Gaston Avenue ( Site 5054)
🇺🇸Dallas, Texas, United States
Baylor College of Medicine Medical Center ( Site 5020)
🇺🇸Houston, Texas, United States
GI Alliance - Lubbock ( Site 5012)
🇺🇸Lubbock, Texas, United States
Caprock Gastro Research ( Site 5077)
🇺🇸Lubbock, Texas, United States
GI Alliance - Southlake ( Site 5109)
🇺🇸Southlake, Texas, United States
Tyler Research Institute ( Site 5001)
🇺🇸Tyler, Texas, United States
Richmond VA Medical Center ( Site 5021)
🇺🇸Richmond, Virginia, United States
Washington Gastroenterology - Bellevue ( Site 5040)
🇺🇸Bellevue, Washington, United States
Swedish Medical Center ( Site 5112)
🇺🇸Seattle, Washington, United States
Washington Gastroenterology - Tacoma ( Site 5004)
🇺🇸Tacoma, Washington, United States
Concord Repatriation General Hospital-Gastroenterology and Liver Services ( Site 3202)
🇦🇺Concord, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 3200)
🇦🇺Brisbane, Queensland, Australia
Royal Adelaide Hosp - GI Clinical Trials ( Site 3203)
🇦🇺Adelaide, South Australia, Australia
Monash Health-Gastroenterology ( Site 3206)
🇦🇺Clayton, Victoria, Australia
The Alfred Hospital-Gastroenterology ( Site 3201)
🇦🇺Melbourne, Victoria, Australia
Medizinische Universitaet Innsbruck-Innere Medizin 1 ( Site 0200)
🇦🇹Innsbruck, Tirol, Austria
Medizinische Universität Wien-Klinik für Innere Medizin III - Abteilung für Gastroenterologie und H ( Site 0202)
🇦🇹Vienna, Wien, Austria
Uniklinikum Salzburg-Innere Medizin I ( Site 0201)
🇦🇹Salzburg, Austria
UZ Gent ( Site 0300)
🇧🇪Gent, Oost-Vlaanderen, Belgium
AZ Delta vzw-Gastroenterology ( Site 0304)
🇧🇪Roeselare, West-Vlaanderen, Belgium
Heritage Medical Research Clinic ( Site 0004)
🇨🇦Calgary, Alberta, Canada
Barrie GI Associates ( Site 0016)
🇨🇦Barrie, Ontario, Canada
G.I.R.I. GI Research Institute Foundation ( Site 0018)
🇨🇦Vancouver, British Columbia, Canada
Victoria Hospital & Children's Hospital - London Health Sciences Centre ( Site 0007)
🇨🇦London, Ontario, Canada
Hospital Clínico Regional Dr. Guillermo Grant Benavente ( Site 2604)
🇨🇱Concepción, Biobio, Chile
FALP-UIDO ( Site 2600)
🇨🇱Santiago, Region M. De Santiago, Chile
West GTA Research Inc. ( Site 0020)
🇨🇦Mississauga, Ontario, Canada
ABP Research Services Corp. ( Site 0019)
🇨🇦Oakville, Ontario, Canada
Toronto Immune & Digestive Health Institute ( Site 0005)
🇨🇦Toronto, Ontario, Canada
Toronto Digestive Disease Associates ( Site 0006)
🇨🇦Vaughan, Ontario, Canada
Diex Recherche Quebec ( Site 0008)
🇨🇦Quebec, Canada
Clínica Alemana de Santiago-Unidad de Investigaciones ( Site 2602)
🇨🇱Santiago, Region M. De Santiago, Chile
Espacio Eme ( Site 2608)
🇨🇱Santiago, Region M. De Santiago, Chile
CECIM ( Site 2603)
🇨🇱Santiago, Region M. De Santiago, Chile
Centro de Investigaciones Clinicas Vina del Mar ( Site 2606)
🇨🇱Vina del Mar, Valparaiso, Chile
Anhui Provincial Hospital ( Site 3922)
🇨🇳Hefei, Anhui, China
Peking University Third Hospital ( Site 3910)
🇨🇳Beijing, Beijing, China
Changzhou No.2 People's Hospital ( Site 3904)
🇨🇳Zhenjiang, Jiangsu, China
Chongqing General Hospital ( Site 3940)
🇨🇳Chongqing, Chongqing, China
The First Affiliated Hospital Of Fujian Medical University ( Site 3916)
🇨🇳Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University ( Site 3924)
🇨🇳XiaMen, Fujian, China
Zhongshan Hospital Affiliated to Xiamen University ( Site 3923)
🇨🇳Xiamen, Fujian, China
Dongguan People's Hospital ( Site 3933)
🇨🇳Dongguan, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University ( Site 3901)
🇨🇳Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 3907)
🇨🇳Guangzhou, Guangdong, China
Huizhou Municipal Central Hospital ( Site 3915)
🇨🇳Huizhou, Guangdong, China
The University of Hong Kong-Shenzhen Hospital ( Site 3930)
🇨🇳Shenzhen, Guangdong, China
Shenzhen Hospital of Southern Medical University ( Site 3932)
🇨🇳Shenzhen, Guangdong, China
The Second Afilliated Hospital of Hebei Medical University ( Site 3913)
🇨🇳Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Zhengzhou University ( Site 3909)
🇨🇳Zhengzhou, Henan, China
Taihe Hospital ( Site 3944)
🇨🇳Shiyan, Hubei, China
Renmin Hospital of Wuhan University ( Site 3921)
🇨🇳Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University-gastroenterology department ( Site 3905)
🇨🇳Changsha, Hunan, China
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 3937)
🇨🇳Nanjing, Jiangsu, China
Zhongda Hospital Southeast University-Gastroenterology ( Site 3911)
🇨🇳Nanjing, Jiangsu, China
Wuxi People's Hospital ( Site 3925)
🇨🇳Wuxi, Jiangsu, China
Affiliated Hospital of Jiangsu University ( Site 3919)
🇨🇳Zhenjiang, Jiangsu, China
Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 3918)
🇨🇳Xian, Shaanxi, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine ( Site 3931)
🇨🇳Shanghai, Shanghai, China
Huashan Hospital of Fudan University ( Site 3946)
🇨🇳Shanghai, Shanghai, China
Shanghai East Hospital ( Site 3914)
🇨🇳Shanghai, Shanghai, China
West China Hospital, Sichuan University ( Site 3929)
🇨🇳Cheng Du, Sichuan, China
Suining Central Hospital ( Site 3927)
🇨🇳SuiNing, Sichuan, China
First Affiliated Hospital of Kunming Medical University ( Site 3928)
🇨🇳Kunming, Yunnan, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-GI Medicine ( Site 3902)
🇨🇳Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 3936)
🇨🇳Taizhou, Zhejiang, China
Clinica Medellin S.A ( Site 2705)
🇨🇴Medellín, Antioquia, Colombia
IMAT S.A.S ( Site 2700)
🇨🇴Monteria, Cordoba, Colombia
Oncologos del Occidente ( Site 2702)
🇨🇴Pereira., Risaralda, Colombia
Fundación Valle del Lili ( Site 2704)
🇨🇴Cali., Valle Del Cauca, Colombia
Poliklinika Solmed ( Site 0502)
🇭🇷Zagreb, Grad Zagreb, Croatia
Poliklinika Borzan ( Site 0500)
🇭🇷Osijek, Osjecko-baranjska Zupanija, Croatia
Herlev and Gentofte Hospital ( Site 5300)
🇩🇰Copenhagen, Hovedstaden, Denmark
Odense Universitetshospital ( Site 5301)
🇩🇰Odense C, Syddanmark, Denmark
Tampereen yliopistollinen sairaala ( Site 5401)
🇫🇮Tampere, Pirkanmaa, Finland
Turku University Hospital ( Site 5402)
🇫🇮Turku, Varsinais-Suomi, Finland
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0711)
🇫🇷Nice, Alpes-Maritimes, France
CHU Bordeaux Haut-Leveque ( Site 0713)
🇫🇷Pessac, Aquitaine, France
Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0722)
🇫🇷Marseille, Bouches-du-Rhone, France
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 0708)
🇫🇷Dijon, Bourgogne, France
Centre Hospitalier Universitaire de Reims - Hôpital Robert Debré ( Site 0707)
🇫🇷Reims cedex, Champagne-Ardenne, France
CHU Besançon ( Site 0724)
🇫🇷Besançon, Doubs, France
Centre Hospitalier de Valence ( Site 0725)
🇫🇷Valence, Drome, France
C.H.U. de Nimes. Hopital Caremeau ( Site 0731)
🇫🇷Nimes, Gard, France
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0702)
🇫🇷Kremlin Bicetre, Ile-de-France, France
centre hospitalier lyon sud ( Site 0716)
🇫🇷Pierre-Bénite, Rhone, France
CHU Rangueil ( Site 0710)
🇫🇷Toulouse, Haute-Garonne, France
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu ( Site 0705)
🇫🇷Nantes, Loire-Atlantique, France
Hopital Beaujon ( Site 0729)
🇫🇷Clichy, Hauts-de-Seine, France
klinikum rechts der isar der technischen universität münchen ( Site 0989)
🇩🇪München, Bayern, Germany
CMC Ambroise Paré Hartmann - Institut des MICI ( Site 0723)
🇫🇷Neuilly-sur-Seine, Hauts-de-Seine, France
CHU SAINT ELOI ( Site 0701)
🇫🇷Montpellier, Languedoc-Roussillon, France
Klinikum Lüneburg ( Site 0991)
🇩🇪Lüneburg, Niedersachsen, Germany
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 0717)
🇫🇷Vandoeuvre-les-Nancy, Meurthe-et-Moselle, France
Hopital Claude Huriez - CHU de Lille ( Site 0715)
🇫🇷Lille, Nord, France
CHU d'Amiens-Picardie - Hôpital Sud ( Site 0709)
🇫🇷Amiens, Somme, France
Hopital Henri Mondor ( Site 0730)
🇫🇷Creteil, Val-de-Marne, France
Hôpital Saint Antoine ( Site 0721)
🇫🇷Paris, France
New Hospitals ( Site 0800)
🇬🇪Tbilisi, Georgia
Caraps Medline ( Site 0803)
🇬🇪Tbilisi, Georgia
Caucasus Medical Centre ( Site 0801)
🇬🇪Tbilisi, Georgia
Klinikum der Universität München Großhadern ( Site 0990)
🇩🇪München, Bayern, Germany
Queen Mary Hospital ( Site 3300)
🇭🇰Hksar, Hong Kong
Siloah St. Trudpert Klinikum-Zentrum für Innere Medizin ( Site 0992)
🇩🇪Pforzheim, Baden-Wurttemberg, Germany
Universitaetsklinikum Ulm. ( Site 0994)
🇩🇪Ulm, Bayern, Germany
Universitätsmedizin Rostock ( Site 0993)
🇩🇪Rostock, Mecklenburg-Vorpommern, Germany
Stadtische Kliniken Duisburg, Abtlg. Innere Medizin ( Site 0985)
🇩🇪Duisburg, Nordrhein-Westfalen, Germany
Evangelisches Krankenhaus Kalk gGmbH ( Site 0986)
🇩🇪Koln, Nordrhein-Westfalen, Germany
Gastroenterologische Gemeinschaftspraxis Minden ( Site 0998)
🇩🇪Minden, Nordrhein-Westfalen, Germany
Medizinische Hochschule Hannover ( Site 0999)
🇩🇪Hannover, Niedersachsen, Germany
Medizinisches Versorgungszentrum Portal 10 ( Site 0988)
🇩🇪Münster, Nordrhein-Westfalen, Germany
St. Marien und St. Annastift Krankenhaus ( Site 0987)
🇩🇪Ludwighafen Am Rhein, Rheinland-Pfalz, Germany
Universitätsklinikum Leipzig ( Site 0997)
🇩🇪Leipzig, Sachsen, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0995)
🇩🇪Kiel, Schleswig-Holstein, Germany
Charité Campus Virchow-Klinikum ( Site 0996)
🇩🇪Berlin, Germany
Städtisches Klinikum Brandenburg ( Site 0903)
🇩🇪Brandenburg, Germany
Evangelismos General Hospital of Athens ( Site 1002)
🇬🇷Athens, Attiki, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1004)
🇬🇷Athens, Attiki, Greece
General Hospital of Nikaia-Piraeus "Agios Panteleimon" ( Site 1003)
🇬🇷Nikaia Piraeus, Attiki, Greece
Ippokrateio General Hospital of Thessaloniki ( Site 1001)
🇬🇷Thessaloniki, Kentriki Makedonia, Greece
University General Hospital of Heraklion-GASTROENTEROLOGY & HEPATOLOGY ( Site 1000)
🇬🇷Heraklion, Kriti, Greece
Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház-4. Belgyogyaszat Gasztroenterologia ( Site 1105)
🇭🇺Békéscsaba, Bekescsaba, Hungary
Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet ( Site 1117)
🇭🇺Eger, Heves, Hungary
Gyöngyösi Bugát Pál Kórház ( Site 1111)
🇭🇺Gyongyos, Heves, Hungary
VeszLife Magánklinika ( Site 1102)
🇭🇺Veszprém, Veszprem, Hungary
Clinexpert Kft.-Clinexpert Budapest ( Site 1108)
🇭🇺Budapest, Hungary
Synexus Magyarorszag Kft. (Budapest DRS) ( Site 1107)
🇭🇺Budapest, Hungary
Pannónia Magánorvosi Centrum ( Site 1103)
🇭🇺Budapest, Hungary
Emek Medical Center ( Site 1206)
🇮🇱Afula, Israel
Barzilai Medical Center ( Site 1209)
🇮🇱Ashkelon, Israel
Rambam Health Care Campus ( Site 1201)
🇮🇱Haifa, Israel
Bnai Zion Medical Center ( Site 1203)
🇮🇱Haifa, Israel
Edith Wolfson Medical Center ( Site 1204)
🇮🇱Holon, Israel
Shaare Zedek Medical Center ( Site 1208)
🇮🇱Jerusalem, Israel
Meir Medical Center. ( Site 1202)
🇮🇱Kfar Saba, Israel
Rabin Medical Center ( Site 1207)
🇮🇱Petah Tikva, Israel
Sheba Medical Center ( Site 1200)
🇮🇱Ramat Gan, Israel
Policlinico Universitario Monserrato-SC Gastroenterologia ( Site 1313)
🇮🇹Monserrato, Cagliari, Italy
Fondazione Policlinico Tor Vergata ( Site 1307)
🇮🇹Rome, Lazio, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico-Gastroenterology and Endoscopy Unit ( Site 1304)
🇮🇹Milano, Lombardia, Italy
Istituto Clinico Humanitas-IBD center ( Site 1309)
🇮🇹Rozzano, Lombardia, Italy
A.O.R.N. Ospedale dei Colli - Monaldi V. ( Site 1310)
🇮🇹Napoles, Napoli, Italy
Ospedale "Felice Lotti" Di Pontedera ( Site 1311)
🇮🇹Pontedera, Pisa, Italy
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-U.O.S.D. Malattie Infiammatorie Croniche Intestinali ( Site 1302)
🇮🇹Palermo, Sicilia, Italy
Ospedale Sacro Cuore Don G. Calabria-IBD Unit ( Site 1303)
🇮🇹Negrar Di Valpolicella, Verona, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1308)
🇮🇹Bologna, Italy
Azienda Ospedaliera Universitaria Di Messina G. Martino ( Site 1314)
🇮🇹Messina, Italy
Ospedale San Raffaele-Gastroenterology and Gastrointestinal Endoscopy ( Site 1300)
🇮🇹Milano, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Dipartimento di Medicina Interna e Gas ( Site 1312)
🇮🇹Roma, Italy
Aichi Medical University Hospital ( Site 3429)
🇯🇵Nagakute, Aichi, Japan
Nagoya University Hospital ( Site 3445)
🇯🇵Nagoya,, Aichi, Japan
Nagoya City University Hospital ( Site 3446)
🇯🇵Nagoya, Aichi, Japan
Tokatsu Tsujinaka Hospital ( Site 3403)
🇯🇵Abiko, Chiba, Japan
National Hospital Organization Fukuyama Medical Center ( Site 3442)
🇯🇵Fukuyama, Hiroshima, Japan
Sapporo Medical University Hospital ( Site 3460)
🇯🇵Sapporo, Hokkaido, Japan
Kanazawa University Hospital ( Site 3436)
🇯🇵Kanazawa, Ishikawa, Japan
Iwate Medical University Uchimaru Medical Center ( Site 3457)
🇯🇵Morioka, Iwate, Japan
Gokeikai Ofuna Chuo Hospital ( Site 3412)
🇯🇵Kamakura, Kanagawa, Japan
Tsujinaka Hospital - Kashiwanoha ( Site 3402)
🇯🇵Kashiwa, Chiba, Japan
Medical Corporation Sapporo IBD Clinic ( Site 3420)
🇯🇵Sapporo, Hokkaido, Japan
Sapporohigashi Tokushukai Hospital ( Site 3441)
🇯🇵Sapporo, Hokkaido, Japan
Toho University Sakura Medical Center ( Site 3413)
🇯🇵Sakura, Chiba, Japan
Kurume University Hospital ( Site 3419)
🇯🇵Kurume, Fukuoka, Japan
Sapporo Tokushukai Hospital ( Site 3427)
🇯🇵Sapporo, Hokkaido, Japan
Gunma University Hospital ( Site 3432)
🇯🇵Maebashi, Gunma, Japan
The Jikei University Hospital ( Site 3414)
🇯🇵Mitato, Tokyo, Japan
Hyogo Medical University Hospital ( Site 3430)
🇯🇵Nishinomiya, Hyogo, Japan
Hitachi General Hospital ( Site 3438)
🇯🇵Hitachi, Ibaraki, Japan
St. Marianna University Hospital ( Site 3440)
🇯🇵Kawasaki, Kanagawa, Japan
Matsushima Hospital ( Site 3450)
🇯🇵Yokohama, Kanagawa, Japan
Yokohama City University Medical Center ( Site 3439)
🇯🇵Yokohama, Kanagawa, Japan
Mie University Hospital ( Site 3405)
🇯🇵Tsu, Mie, Japan
University of the Ryukyus Hospital ( Site 3459)
🇯🇵Ginowan, Okinawa, Japan
Tohoku University Hospital ( Site 3447)
🇯🇵Sendai, Miyagi, Japan
Kagoshima IBD Gastroenterology Clinic ( Site 3428)
🇯🇵Kagoshima, Japan
Kansai Medical University Hospital ( Site 3409)
🇯🇵Hirakata, Osaka, Japan
Matsuda Hospital ( Site 3404)
🇯🇵Hamamatsu, Shizuoka, Japan
National Hospital Organization Shizuoka Medical Center ( Site 3401)
🇯🇵Shimizu, Shizuoka, Japan
Saitama Medical Center ( Site 3452)
🇯🇵Kawagoe, Saitama, Japan
Hamamatsu University Hospital ( Site 3449)
🇯🇵Hamamatsu, Shizuoka, Japan
Institute of Science Tokyo Hospital ( Site 3437)
🇯🇵Bunkyō, Tokyo, Japan
Ginza Central Clinic ( Site 3407)
🇯🇵Chuo, Tokyo, Japan
Kitasato University Kitasato Institute Hospital ( Site 3458)
🇯🇵Minato, Tokyo, Japan
Kyorin University Hospital ( Site 3443)
🇯🇵Mitaka, Tokyo, Japan
Tokyo Medical University Hospital ( Site 3456)
🇯🇵Shinjuku, Tokyo, Japan
National Center for Global Health and Medicine ( Site 3423)
🇯🇵Shinjuku, Tokyo, Japan
Yamanashi Prefectural Central Hospital ( Site 3435)
🇯🇵Kofu, Yamanashi, Japan
Fukuoka University Hospital ( Site 3417)
🇯🇵Fukuoka, Japan
Hiroshima University Hospital ( Site 3418)
🇯🇵Hiroshima, Japan
Kagoshima University Hospital ( Site 3425)
🇯🇵Kagoshima, Japan
University Hospital,Kyoto Prefectural University of Medicine ( Site 3406)
🇯🇵Kyoto, Japan
National Hospital Organization Kyoto Medical Center ( Site 3411)
🇯🇵Kyoto, Japan
Okayama University Hospital ( Site 3454)
🇯🇵Okayama, Japan
Infusion Clinic ( Site 3408)
🇯🇵Osaka, Japan
National Hospital Organization Osaka National Hospital ( Site 3453)
🇯🇵Osaka, Japan
Saga University Hospital ( Site 3424)
🇯🇵Saga, Japan
Tokyo Yamate Medical Center ( Site 3415)
🇯🇵Tokyo, Japan
Toyama Prefectural Central Hospital ( Site 3410)
🇯🇵Toyama, Japan
Yamagata University Hospital ( Site 3426)
🇯🇵Yamagata, Japan
Wonju Severance Christian Hospital-Internal Medicine ( Site 3600)
🇰🇷Wonju, Kang-won-do, Korea, Republic of
The Catholic University Of Korea St. Vincent's Hospital-Gastroenterology ( Site 3608)
🇰🇷Suwon-si, Kyonggi-do, Korea, Republic of
Dong-A University Hospital ( Site 3601)
🇰🇷Busan, Pusan-Kwangyokshi, Korea, Republic of
Inje University Haeundae Paik Hospital ( Site 3605)
🇰🇷Haeundae-gu, Pusan-Kwangyokshi, Korea, Republic of
Chung-Ang University Hospital ( Site 3606)
🇰🇷Dongjak-gu, Seoul, Korea, Republic of
Yeungnam Univeristy Medical Center ( Site 3610)
🇰🇷Daegu, Taegu-Kwangyokshi, Korea, Republic of
The Catholic University of Korea, Daejeon St. Mary's Hospital ( Site 3604)
🇰🇷Daejeon, Taejon-Kwangyokshi, Korea, Republic of
Kyung Hee University Hospital ( Site 3611)
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital ( Site 3607)
🇰🇷Seoul, Korea, Republic of
Kangbuk Samsung Hospital-Internal Medicine ( Site 3612)
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3602)
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System-Department of Internal Medicine ( Site 3603)
🇰🇷Seoul, Korea, Republic of
Asan Medical Center ( Site 3609)
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center ( Site 3613)
🇰🇷Seoul, Korea, Republic of
Hospital of Lithuanian University of Health Sciences Kauno klinikos-Gastroenterology ( Site 6000)
🇱🇹Kaunas, Kauno Apskritis, Lithuania
Hospital Sultanah Aminah ( Site 6104)
🇲🇾Johor Bahru, Johor, Malaysia
Hospital Universiti Sains Malaysia ( Site 6103)
🇲🇾Kubang Kerian, Kelantan, Malaysia
University Malaya Medical Centre ( Site 6101)
🇲🇾Lembah Pantai, Kuala Lumpur, Malaysia
Sarawak General Hospital ( Site 6102)
🇲🇾Kuching, Sarawak, Malaysia
Hospital Ampang ( Site 6106)
🇲🇾Ampang, Selangor, Malaysia
Centro de Investigación y Gastroenterología - S.C. ( Site 3102)
🇲🇽Ciudad de Mexico, Distrito Federal, Mexico
Morales Vargas Centro de Investigacion ( Site 3101)
🇲🇽Leon, Guanajuato, Mexico
Centro Medico Clinico Quirurgico Especializado en Investigación ( Site 3106)
🇲🇽Tlajomulco de Zúñiga, Jalisco, Mexico
Servicios de Oncología Médica Integral, S.A de C.V. ( Site 3108)
🇲🇽San Pedro Garza Garcia, Nuevo Leon, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 3105)
🇲🇽Oaxaca de Juarez, Oaxaca, Mexico
Medical Care and Research SA de CV-GASTROENTEROLOGY ( Site 3110)
🇲🇽Merida, Yucatan, Mexico
Radboudumc ( Site 1505)
🇳🇱Nijmegen, Gelderland, Netherlands
Hutt Valley District Health board HVDHB ( Site 3500)
🇳🇿Lower Hutt, Wellington, New Zealand
Aotearoa Clinical Trials ( Site 3501)
🇳🇿Auckland, New Zealand
Hospital Cayetano Heredia ( Site 3003)
🇵🇪Lima, Peru
ETZ Elisabeth ( Site 1501)
🇳🇱Tilburg, Noord-Brabant, Netherlands
Ziekenhuis Bernhoven ( Site 1508)
🇳🇱Uden, Noord-Brabant, Netherlands
Amsterdam UMC, locatie VUmc-IBD Trial Unit ( Site 1500)
🇳🇱Amsterdam, Noord-Holland, Netherlands
Erasmus Medisch Centrum ( Site 1504)
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Franciscus Gasthuis & Vlietland, Locatie Gasthuis ( Site 1503)
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Investigaciones Clínicas / Instituto de Ginecología y Reproducción ( Site 3002)
🇵🇪Lima, Peru
Amicare ( Site 1620)
🇵🇱Jelenia Gora, Dolnoslaskie, Poland
Planetmed ( Site 1600)
🇵🇱Wroclaw, Dolnoslaskie, Poland
Melita Medical ( Site 1607)
🇵🇱Wroclaw, Dolnoslaskie, Poland
EMC Instytut Medyczny SA ( Site 1601)
🇵🇱Wroclaw, Dolnoslaskie, Poland
Gastromed Sp. z o. o. ( Site 1619)
🇵🇱Torun, Kujawsko-pomorskie, Poland
Centrum Medyczne Med-Gastr Sp. z o.o. ( Site 1616)
🇵🇱Lodz, Lodzkie, Poland
AmiCare Sp. z o.o. Sp. k. ( Site 1608)
🇵🇱Lodz, Lodzkie, Poland
Allmedica ( Site 1602)
🇵🇱Nowy Targ, Malopolskie, Poland
Centrum Zdrowia MDM ( Site 1618)
🇵🇱Warszawa, Mazowieckie, Poland
WIP Warsaw IBD Point Profesor Kierkuś ( Site 1622)
🇵🇱Warszawa, Mazowieckie, Poland
University Medical Center Groningen ( Site 1506)
🇳🇱Groningen, Netherlands
Universitair Medisch Centrum Utrecht ( Site 1502)
🇳🇱Utrecht, Netherlands
Dunedin Hospital ( Site 3505)
🇳🇿Dunedin, Otago, New Zealand
H-T Centrum Medyczne Endoterapia ( Site 1610)
🇵🇱Tychy, Slaskie, Poland
PL Certus ( Site 1605)
🇵🇱Poznan, Wielkopolskie, Poland
Pratia Poznań ( Site 1603)
🇵🇱Poznań, Wielkopolskie, Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne ( Site 1612)
🇵🇱Szczecin, Zachodniopomorskie, Poland
Sonomed Sp. z o. o. ( Site 1617)
🇵🇱Szczecin, Zachodniopomorskie, Poland
Unidade Local de Saúde do Alto Ave - Hospital Senhora da Oliveira ( Site 1704)
🇵🇹Guimaraes, Braga, Portugal
Unidade Local de Saude do Algarve - Hospital de Portimão ( Site 1700)
🇵🇹Portimão, Faro, Portugal
Unidade Local de Saude da Região de Leiria - Hospital Santo André ( Site 1706)
🇵🇹Leiria, Portugal
Hospital da Luz Lisboa ( Site 1707)
🇵🇹Lisboa, Portugal
Hospital dos Lusíadas Lisboa ( Site 1701)
🇵🇹Lisboa, Portugal
ULSAM - Hospital de Santa Luzia ( Site 1703)
🇵🇹Viana do Castelo, Portugal
Unidade Local de Saude Dão-Lafões - Hospital de São Teotónio ( Site 1702)
🇵🇹Viseu, Portugal
MEMORIAL HEALTHCARE INTERNATIONAL S.R.L ( Site 1806)
🇷🇴Bucharest, Bucuresti, Romania
Fundeni Clinical Institute-Gastroenterology and Hepatology Center ( Site 1808)
🇷🇴București, Bucuresti, Romania
GastroMed ( Site 1809)
🇷🇴Cluj-Napoca, Cluj, Romania
Spitalul Clinic Judetean Mures-Gastroenterology ( Site 1807)
🇷🇴Targu Mures, Mures, Romania
ASOCIATIA ONCOHELP ( Site 1805)
🇷🇴Timisoara, Timis, Romania
S.C. Centrul Medical Medicum SRL-Gastroenterology ( Site 1804)
🇷🇴Bucuresti, Romania
General Hospital "Djordje Joanovic" ( Site 1905)
🇷🇸Zrenjanin, Srednjebanatski Okrug, Serbia
Singapore General Hospital ( Site 6202)
🇸🇬Singapore, Central Singapore, Singapore
Tan Tock Seng Hospital-Gastroenterology and Hepatology ( Site 6201)
🇸🇬Singapore, Central Singapore, Singapore
Changi General Hospital ( Site 6203)
🇸🇬Singapore, South East, Singapore
Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica-Gastroenterologicke oddelenie ( Site 2002)
🇸🇰Banska Bystrica, Banskobystricky Kraj, Slovakia
Cliniq s.r.o. ( Site 2001)
🇸🇰Bratislava, Bratislavsky Kraj, Slovakia
KM Management ( Site 2000)
🇸🇰Nitra, Nitriansky Kraj, Slovakia
Panorama Medical Centre ( Site 4001)
🇿🇦Cape Town, Western Cape, South Africa
Spoke Research ( Site 4003)
🇿🇦Cape Town, Western Cape, South Africa
Life Kingsbury Hospital ( Site 4000)
🇿🇦Cape Town, Western Cape, South Africa
Private Practice - Dr. M.N. Rajabally ( Site 4007)
🇿🇦Plumstead, Western Cape, South Africa
Hospital Germans Trias i Pujol ( Site 2101)
🇪🇸Badalona, Barcelona, Spain
HOSPITAL CLÍNIC DE BARCELONA-ICMDM - Clinical Institute of Digestive and Metabolic Diseases ( Site 2112)
🇪🇸Barcelona, Cataluna, Spain
Hospital Universitario Puerta de Hierro ( Site 2102)
🇪🇸Majadahonda, Madrid, Spain
Hospital Universitario de Torrejón ( Site 2108)
🇪🇸Torrejón de Ardoz, Madrid, Spain
Hospital Universitario La Paz ( Site 2100)
🇪🇸Madrid, Spain
Hospital Montecelo. Complexo Hospitalario de Pontevedra ( Site 2107)
🇪🇸Pontevedra, Spain
Hospital Universitario Nuestra Senora de la Candelaria ( Site 2105)
🇪🇸Santa Cruz de Tenerife, Spain
HOSPITAL CLINICO DE VALENCIA-MEDICINA DIGESTIVA ( Site 2103)
🇪🇸Valencia, Spain
Hospital Universitari i Politecnic La Fe ( Site 2111)
🇪🇸Valencia, Spain
Hospital Universitario Miguel Servet ( Site 2104)
🇪🇸Zaragoza, Spain
Universitetssjukhuset i Linköping ( Site 5502)
🇸🇪Linköping, Ostergotlands Lan, Sweden
Danderyds Sjukhus ( Site 5501)
🇸🇪Danderyd, Stockholms Lan, Sweden
Karolinska Universitetssjukhuset Solna ( Site 5500)
🇸🇪Stockholm, Stockholms Lan, Sweden
University Hospital Basel-Gastroenterology and Hepatology ( Site 2204)
🇨🇭Basel, Basel-Stadt, Switzerland
INTESTO-Gastroenterologische Praxis / Crohn-Colitis Zentrum Bern ( Site 2202)
🇨🇭Bern, Berne, Switzerland
Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 2201)
🇨🇭St.Gallen, Sankt Gallen, Switzerland
UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 2200)
🇨🇭Zürich, Zurich, Switzerland
National Taiwan University BioMedical Park Hospital ( Site 3702)
🇨🇳Zhu Bei City, Hsinchu, Taiwan
National Taiwan University Hospital-Internal Medicine ( Site 3700)
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 3701)
🇨🇳Taoyuan, Taiwan
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 2300)
🇹🇷Ankara, Turkey
ANKARA UNIVERSITY IBNI SINA HOSPITAL-Gastroenterology ( Site 2303)
🇹🇷Ankara, Turkey
Ankara Bilkent Şehir Hastanesi-Gastroenterology ( Site 2301)
🇹🇷Ankara, Turkey
Antalya Egitim ve Arastırma Hastanesi ( Site 2304)
🇹🇷Antalya, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi Hastanesi ( Site 2306)
🇹🇷Istanbul, Turkey
Marmara Univetsitesi Pendik Egitim ve Arastirma Hastanesi ( Site 2305)
🇹🇷Istanbul, Turkey
Ege Universitesi Hastanesi ( Site 2302)
🇹🇷İzmir, Turkey
Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 5815)
🇺🇦Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine
Medical Center of Limited ( Site 5806)
🇺🇦Kyiv, Kyivska Oblast, Ukraine
Center of Family Medicine Plus ( Site 5803)
🇺🇦Kyiv, Kyivska Oblast, Ukraine
Communal Non-profit Enterprise of Lviv Regional Council "Lviv Regional Clinical Hospital"-proctology ( Site 5809)
🇺🇦Lviv, Lvivska Oblast, Ukraine
Limited liability company "Medical center Health Clinic" ( Site 5807)
🇺🇦Vinnytsia, Vinnytska Oblast, Ukraine
Clinic of Scientific and Research Institute of Invalid Rehabilitation of VNMU n.a. M.I.Pyrohov ( Site 5812)
🇺🇦Vinnytsia, Vinnytska Oblast, Ukraine
Communal Non-Commercial Enterprise "Vinnytsia City Clinical -Clinical Therapeutic Department #1 ( Site 5811)
🇺🇦Vinnytsia, Vinnytska Oblast, Ukraine
Municipal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital n.a. M. I. Pyrohov of Vinnytsia ( Site 5814)
🇺🇦Vinnytsya, Vinnytska Oblast, Ukraine
Municipal Enterprise "Volyn Regional Clinical Hospital" of Volyn Regional Council ( Site 5813)
🇺🇦Lutsk, Volynska Oblast, Ukraine
Medical Center "Universal Clinic "Oberig" of Limited Liability Company "Kapytal" ( Site 5800)
🇺🇦Kyiv, Ukraine
Medical Center of Private Enterprise "Sygma" ( Site 5808)
🇺🇦Kyiv, Ukraine
Royal Devon & Exeter Hospital ... ( Site 2407)
🇬🇧Exeter, Devon, United Kingdom
Dobrobut Medical Center ( Site 5801)
🇺🇦Kyiv, Ukraine
Doncaster Royal Infirmary ( Site 2401)
🇬🇧Doncaster, England, United Kingdom
Huddersfield Royal Infirmary ( Site 2409)
🇬🇧Huddersfield, England, United Kingdom
Whipps Cross University Hospital-Clinical Research Unit ( Site 2404)
🇬🇧London, England, United Kingdom
The John Radcliffe Hospital ( Site 2406)
🇬🇧Oxford, Oxfordshire, United Kingdom
Walsall Manor Hospital ( Site 2410)
🇬🇧West Midlands, Walsall, United Kingdom